Monte Rosa Therapeutics is a clinical-stage company developing MRT-8102, a pill that switches off the NLRP3 inflammation pathway, for heart disease, gout and hidradenitis suppurativa; it is not approved.
Monte Rosa's case rests on oral NEK7 degrader MRT-8102 turning inflammation-marker reductions into patient benefit across gout, hidradenitis suppurativa and coronary artery disease. GFORCE-1 supports its biological activity and short-term tolerability; disease-specific trials remain the next step. Novartis's MRT-6160 studies and milestone payments broaden the opportunity, while MRT-2359 adds oncology potential. Management expects existing resources to support operations into 2029, with future partnered development carrying co-funding obligations.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: GFORCE-2 starts in coronary artery disease in 1H 2027
Can regulatory feedback and long-term toxicology support GFORCE-2 initiation on the planned schedule?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Novartis broadens MRT-6160 development; MRT-8102 remains central to Monte Rosa's case
Molecular glue degrader targeting NLRP3 inflammasome enters Phase 2 across three indications; proof-of-concept data quality determines whether the platform justifies its $626M balance sheet
MRT-8102's 85% CRP reduction in Phase 1 positions it as a NEK7-directed NLRP3 degrader; Phase 2 efficacy across CVD and HS will prove or disprove the thesis
MRT-8102 Phase 1 interim data: 85% CRP reduction in CVD-risk subjects
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Breast and gynecologic cancers, Other cancers, Neurology and pain, Obesity, diabetes and heart disease, Skin diseases, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
22 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.